Home > Insider Trading > Filing (0001358403-16-000231)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1358403	Bellicum Pharmaceuticals Inc	BLCM	Pharmaceutical Preparations (2834)	201450200

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1626808	M. Kevin Slawin	C/O Bellicum Pharmaceuticals, Inc. 2130 W. Holcombe Blvd., Ste. 800 Houston TX 77030	Chief Technology Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-07-15	22,281	$13.72	136,925	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	414,982	Indirect	By the Jordana Slawin 2012 Family Trust
Common Stock	398,067	Indirect	By the Kevin Slawin 2009 Family Trust

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 23, 2016 by the Reporting Person.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.51 to $13.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The Reporting Person's spouse is trustee of the Jordana Slawin 2012 Family Trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.